Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinxue Liu

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
BMJ Open|January 27, 2026
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against <i>Salmonella</i> Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocolMargarete Paganotti Vicentine, Naina McCann, Oisin Hennigan, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
The New England Journal of Medicine|October 29, 2025
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A VaccineNaina McCann, Margarete Paganotti Vicentine, Narges Ebrahimi, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
The Lancet. Microbe|February 16, 2026
The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trialKonstantinos Liatsikos, Angela Hyder-Wright, Kelly Davies, et al.
Emerging Infectious Diseases|September 28, 2025
Comparative Epidemiology of Salmonella enterica Serovers Paratyphi A and Typhi Causing Enteric Fever, Bangladesh, 2018-2020Sadia Isfat Ara Rahman, Md Golam Firoj, Se Eun Park, et al.
Lancet (London, England)|August 13, 2021
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trialFirdausi Qadri, Farhana Khanam, Xinxue Liu, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
BMC Infectious Diseases|January 31, 2025
Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, BangladeshFarhana Khanam, Natasha Y Rickett, Faisal Ahmmed, et al.
The Lancet. Global Health|October 22, 2021
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trialMila Shakya, Merryn Voysey, Katherine Theiss-Nyland, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
BMJ Open|January 27, 2026
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against <i>Salmonella</i> Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocolMargarete Paganotti Vicentine, Naina McCann, Oisin Hennigan, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
The New England Journal of Medicine|October 29, 2025
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A VaccineNaina McCann, Margarete Paganotti Vicentine, Narges Ebrahimi, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
The Lancet. Microbe|February 16, 2026
The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trialKonstantinos Liatsikos, Angela Hyder-Wright, Kelly Davies, et al.
Emerging Infectious Diseases|September 28, 2025
Comparative Epidemiology of Salmonella enterica Serovers Paratyphi A and Typhi Causing Enteric Fever, Bangladesh, 2018-2020Sadia Isfat Ara Rahman, Md Golam Firoj, Se Eun Park, et al.
Lancet (London, England)|August 13, 2021
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trialFirdausi Qadri, Farhana Khanam, Xinxue Liu, et al.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
BMC Infectious Diseases|January 31, 2025
Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, BangladeshFarhana Khanam, Natasha Y Rickett, Faisal Ahmmed, et al.
The Lancet. Global Health|October 22, 2021
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trialMila Shakya, Merryn Voysey, Katherine Theiss-Nyland, et al.
Pageof 10